The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit ...

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, ...

Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ("Replimune or the "Company") (NASDAQ: REPL).

Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

Fintel reports that on July 22, 2025, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 725.97% Upside As of July 17, ...

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...

Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...